Phase II Clinical Trial Presented at American Diabetes Association Meeting Shows BCG Can Improve Blood Sugar Regulation
A vaccine developed in the 1920s to fight tuberculosis has demonstrated the ability to improve blood sugar regulation and reduce insulin dependency in people with autoimmune forms of diabetes, according to new results from a phase II clinical trial. The findings, presented by Dr Denise Faustman of Massachusetts General Hospital and Harvard Medical School at the American Diabetes Association meeting on June 7 in New Orleans, reveal that the Bacillus Calmette-Gu'rin (BCG) vaccine can help regulate blood sugar in patients with type 1 diabetes and latent autoimmune diabetes in adults (LADA).
The century-old vaccine, best known for its role in tuberculosis prevention, appears to influence the immune system by promoting regulatory T-cells and shifting metabolic processes. The research suggests BCG may help "reset" parts of the immune response, reducing inflammation and supporting better blood sugar control without relying solely on external insulin.
How BCG Works: Recalibrating the Immune System
The mechanism behind BCG's effect on diabetes is rooted in immunometabolism. In type 1 diabetes, the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. BCG appears to promote a more balanced immune response by increasing regulatory T-cells, which help prevent autoimmune reactions, and by reducing the number of autoreactive immune cells that target pancreatic beta cells.
Additionally, BCG induces a metabolic shift towards aerobic glycolysis in immune cells ' essentially correcting a fundamental metabolic defect in the white blood cells of type 1 diabetics. This shift allows the body to maintain better overall glucose regulation. Clinical trials have demonstrated meaningful reductions in HbA1c levels, a key marker of long-term blood glucose control, among patients receiving multi-dose BCG immunotherapy.
Notably, patients who received the vaccine reported no severe hypoglycemia despite maintaining low blood glucose levels, while those who did not receive the vaccine continued to experience hypoglycemic events. This safety profile is particularly significant because severe hypoglycemia is one of the most dangerous complications of insulin therapy.
India Angle: A Low-Cost Solution for the World's Diabetes Capital
India is often referred to as the diabetes capital of the world, with an estimated 101 million people living with diabetes as of 2025, according to the Indian Council of Medical Research (ICMR). The country accounts for nearly one in every seven adults with diabetes globally. Type 1 diabetes, while less common than type 2, affects an estimated 1.5-2 million Indians, many of whom face lifelong insulin dependency and its associated costs.
BCG is one of the world's most affordable vaccines ' it costs approximately Rs 30-40 per dose in India and is already produced domestically by the Serum Institute of India and other manufacturers. If larger phase III trials confirm efficacy, repurposing BCG for diabetes management could offer a dramatically more accessible treatment pathway for millions of Indian patients who currently struggle with the cost and logistics of insulin therapy.
The BCG vaccine is already part of India's universal immunisation programme for tuberculosis prevention, meaning the manufacturing infrastructure, cold chain logistics, and clinical administration protocols are already well-established across the country's healthcare system. This existing infrastructure could significantly accelerate deployment if BCG receives regulatory approval for diabetes indications.
The Road Ahead: Phase III Trials Needed
While the phase II results are encouraging, researchers caution that larger, multi-centre phase III trials are needed before BCG can be recommended as a standard therapy for diabetes. The current findings are based on relatively small patient cohorts, and longer-term data on durability of effect and optimal dosing regimens are still being collected.
Dr Faustman's team has been investigating BCG's metabolic effects for over two decades. The vaccine was originally observed to have unexpected benefits on blood sugar control in tuberculosis patients who also had diabetes, leading to the hypothesis that its immunomodulatory effects could extend beyond infectious disease. The current trial results represent the most compelling evidence to date supporting that hypothesis.
The research has attracted attention partly because BCG is a generic vaccine with no commercial patent holder, meaning that if proven effective, it would be available at minimal cost ' a stark contrast to newer diabetes therapies that can cost thousands of dollars annually.
Sources
- News18 ' In A Scientific Breakthrough, A 100-Year-Old TB Vaccine Could Help Treat Diabetes (news18.com)
- Gulf News ' Century-old TB vaccine could reduce insulin use in diabetes patients, trial finds (gulfnews.com)
- US Pharmacist ' Does TB Vaccine Reverse Diabetes? (uspharmacist.com)
- Scientia Global ' Dr Denise Faustman: An Unexpected Ally in the Fight Against Diabetes (scientia.global)
See also: World Cup Day 5 Preview: Belgium vs Egypt, Iran vs New Zeala · Astronomers Finally Discover Milky Way's Missing Black Hole
